Get a Head Start On Your 2024 Preclinical Drug Development Program

EXPERTISE Matters.

With four strategically placed preclinical research facilities throughout North America, Altasciences can get your CTA/IND-enabling studies underway in just 8 weeks!

We offer a full range of in vivo non-GLP and GLP preclinical studies in both rodent and non-rodent species, to assess the safety of your small and large molecules in support of upcoming first-in-human clinical trials.

Our IND/NDA-enabling studies include:

      •   lead identification and optimization
      •   dose-range finding 
      •   pivotal toxicology (acute, sub-chronic, chronic, carcinogenicity)       •   pharmacology/safety pharmacology 
      •   bioanalysis

Time is of the essence―let’s get started!

Related resources that may interest you:

•   eBook: Nonclinical Safety Testing Guide 
•   Scientific Journal: IND Checklist for Your Preclinical Assessment
•   Webinar: Selecting the Right Species for Your Toxicology Program